In a MELD-based economy, how can we fight off inflation?

Liver Transplantation

Volumn 13, Issue 1, 2007, Pages 2-4

  Biggins, Scott W ^a,b   Feng, Sandy ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CREATININE;

CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CONSENSUS; DISEASE SEVERITY; DONOR; ECONOMIC ASPECT; EDITORIAL; FATALITY; GRAFT SURVIVAL; HEALTH CARE POLICY; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MORTALITY; PATIENT SELECTION; PRIORITY JOURNAL;

COSTS AND COST ANALYSIS; HUMANS; INFLATION, ECONOMIC; LIVER DISEASES; LIVER FAILURE; LIVER TRANSPLANTATION; RESOURCE ALLOCATION; RISK; TISSUE AND ORGAN PROCUREMENT; WAITING LISTS;

EID: 33846190184     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21008     Document Type: Editorial

References (17)

1. UNOS. Organ distribution: Allocation of livers. Policy 3.6. Available at: http://www.unos.org/policiesandbylaws/policies.asp?resources=true. Last accessed: August 24, 2006.
2. Heuman DM, Milhas AA, Habib A, Gilles H, Stravitz RT, Sanyal AJ, Fisher RA. MELD-XI: a rational approach to "sickest first" liver transplantation in cirrhotic patients requiring anticoagulation therapy. Liver Transpl 13:30-37.
3. Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA. The survival benefit of liver transplantation. Am J Transplant 2005;5:307-313.
4. Trotter JF, Brimhall B, Arjal R, Phillips C. Specific laboratory methodologies achieve higher Model For End-Stage Liver Disease (MELD) scores for patients listed for liver transplantation. Liver Transpl 2004;10:995-1000.
5. Kamath P, Wiesner R, Malinchoc M, Kremers W, Therneau T, Kosberg C. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-470.
6. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, et al. Model for End-Stage Liver Disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-96.
7. Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, Benson J, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006;130:1652-1660.
8. Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, Lucey MR. Model for End-Stage Liver Disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 2004;40:897-903.
9. Freeman RB, Wiesner RH, Edwards E, Harper A, Merion R, Wolfe R. Results of the first year of the new liver allocation plan. Liver Transpl 2004:10:7-15.
10. Freeman RB, Harper A, Edwards EB. Excellent liver transplant survival rates under the MELD/PELD system. Transplant Proc 2005:37:585-588.
11. Biggins SW, Bambha K. MELD-based liver allocation: who is underserved? Semin Liver Dis 2006;26:211-220.
12. Kremers WK, Van IM, Kim WR, Freeman RB, Harper AM, Kamath PS, Wiesner RH. MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients. Hepatology 2004;39:764-769.
13. O'Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet 1993;342:273-275.
14. Saab S, Niho H, Comulada S, Hiatt J, Durazo F, Han S, et al. Mortality predictors in liver transplant recipients with recurrent hepatitis C cirrhosis. Liver Int 2005;25:940-945.
15. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-649.
16. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31:864-871.
17. Oniscu GC, Brown H, Forsythe JL. Impact of cadaveric renal transplantation on survival in patients listed for transplantation. J Am Soc Nephrol 2005;16:1859-1865.